LFMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
LifeMD Inc (LFMD) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is facing significant headwinds from competitive pressures, declining financial performance, and bearish technical indicators. While analysts maintain a Buy rating, the reduced price targets and lack of immediate positive catalysts suggest waiting for more clarity on growth reacceleration in 2026.
The technical indicators for LFMD are bearish. The MACD histogram is negative and expanding downward, RSI is neutral but leaning toward oversold territory, and moving averages are in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 2.801, with resistance at 3.065. Overall, the technical setup does not indicate a strong entry point.
Analysts expect growth to reaccelerate in 2026 due to partnerships with Eli Lilly and Novo, stricter enforcement against low-cost compounders, and the launch of oral Wegovy.
Revenue increased by 12.95% YoY in Q3 2025.
Competitive pressures from low-cost compounders have impacted the weight management business.
Financial performance has weakened, with net income and EPS declining YoY.
Analysts have significantly lowered price targets, reflecting reduced near-term growth expectations.
No recent news or congress trading data to indicate immediate interest or support.
In Q3 2025, revenue grew by 12.95% YoY to $60.17M. However, net income dropped by 15.67% YoY to -$4.58M, and EPS declined by 23.08% YoY to -$0.1. Gross margin also fell slightly to 87.69%, down 3.20% YoY. The financials indicate growth in revenue but worsening profitability.
Analysts maintain a Buy rating but have significantly lowered price targets due to competitive pressures and revised guidance. Price targets now range from $8 to $10, down from $12 to $18 previously. Analysts expect growth to reaccelerate in 2026, but near-term challenges persist.
